Background: Lymphoid enhancer-binding factor-1 (LEF1) is a member of the LEF/T-cell factor family of transcription factors and a key mediator of the Wingless-type (Wnt) pathway. It mediates Wnt signals through recruiting β-catenin and its co-activators to Wnt response elements of target genes. It plays crucial roles in normal hematopoiesis, not only in the development of B and T lymphocytes but also in granulopoiesis. Objectives: The aim of this study was to evaluate of LEF1 expression levels in patients with AML and correlate this expression with clinical data. Methodology: The present study was conducted on 30 de novo adult AML patients and 10 age and sex-matched controls with non-malignant hematological disorders (e.g.: hypersplenism, megaloblastic anemia, immune thrombocytopenic purpura) who attended Hematology/Oncology unit of Ain-Shams University Hospitals during the period from May 2017 till January 2018, after taking the approval of the Scientific and Ethical Committee of Ain- Shams University. LEF1 expression levels were measured by quantitative real-time PCR. Results: The present study showed that there was highly statistically significant association between patients and control group in LEF1 expression level. There was positive significant correlation between LEF1 expression level and Hb level and PLT count. While negative significant correlation was found with age, TLC count and peripheral blood blast %. No correlation was found with bone marrow blasts %. There was statistically significant difference between LEF1 expression level and both hepatosplenomegaly. No statistically significant difference was found between LEF1 expression level and Sex or lymphadenopathy. Conclusion: Our study has shown that Lymphoid Enhancer-Binding Factor 1 (LEF-1) is over expressed in AML patients. LEF1 expression might be involved in the process of disease progression, and possibly can serve as a molecular parameter for risk assessment and/or monitoring of treatment in AML patients. Thus, molecular assessment of LEF1 expression at diagnosis may be of value to add to the prognostic work of AML patients.
Shalaby, N. A., Eissa, D. A. G., Farweez, B. A. T., Pessar, S. A., & Galal, R. E. S. A. M. (2018). Clinical Significance of Lymphoid Enhancer-Binding Factor 1 (LEF-1) Expression in Acute Myeloid Leukemia. The Egyptian Journal of Hospital Medicine, 72(6), 4686-4692. doi: 10.21608/ejhm.2018.9841
MLA
Nahela Ahmed Shalaby; Doaa Ahmed Gamal Eissa; Botheina Ahmed Thabet Farweez; Shaimaa Abdelmalik Pessar; Raghda El Sayed Abdel Monem Galal. "Clinical Significance of Lymphoid Enhancer-Binding Factor 1 (LEF-1) Expression in Acute Myeloid Leukemia", The Egyptian Journal of Hospital Medicine, 72, 6, 2018, 4686-4692. doi: 10.21608/ejhm.2018.9841
HARVARD
Shalaby, N. A., Eissa, D. A. G., Farweez, B. A. T., Pessar, S. A., Galal, R. E. S. A. M. (2018). 'Clinical Significance of Lymphoid Enhancer-Binding Factor 1 (LEF-1) Expression in Acute Myeloid Leukemia', The Egyptian Journal of Hospital Medicine, 72(6), pp. 4686-4692. doi: 10.21608/ejhm.2018.9841
VANCOUVER
Shalaby, N. A., Eissa, D. A. G., Farweez, B. A. T., Pessar, S. A., Galal, R. E. S. A. M. Clinical Significance of Lymphoid Enhancer-Binding Factor 1 (LEF-1) Expression in Acute Myeloid Leukemia. The Egyptian Journal of Hospital Medicine, 2018; 72(6): 4686-4692. doi: 10.21608/ejhm.2018.9841
)
View on SCiNiTO